- $1.63bn
- $3.68bn
- $1.76bn
- 37
- 96
- 40
- 59
Annual income statement for Endo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 2,993 | 2,319 | 2,012 | 1,760 |
| Cost of Revenue | ||||
| Gross Profit | 1,772 | 1,226 | 1,065 | 316 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Operating Interest Expense / Income | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 3,557 | 5,213 | 4,404 | -3,632 |
| Operating Profit | -564 | -2,894 | -2,393 | 5,392 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -547 | -2,888 | -2,392 | 5,387 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -569 | -2,910 | -2,448 | 5,460 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -613 | -2,923 | -2,450 | 5,642 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -613 | -2,923 | -2,450 | 5,642 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.571 | -13.4 | -8.46 | 26.8 |
| Dividends per Share |